BGNE BeiGene Ltd.

122.91
+0.21  (+0%)
Previous Close 122.7
Open 123
Price To Book 4.58
Market Cap 7,362,807,646
Shares 59,904,057
Volume 175,120
Short Ratio
Av. Daily Volume 283,579

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrolment to be completed in 2019.
Tislelizumab
Hepatocellular carcinoma (HCC)
Phase 2 pivotal trial data due late 2019 or early 2020 (China).
Pamiparib (BGB-290)
Ovarian Cancer
Phase 3 data from 17p del cohort due 2H 2019.
Zanubrutinib (BGB-3111) with Bendamustine Plus Rituximab
First-line chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Phase 1b data presented at ICML June 20, 2019 noted ORR 72-100%. Phase 2 trial is ongoing.
Zanubrutinib and Obinutuzumab
Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Phase 3 trial to be initiated 1H 2018.
Pamiparib (BGB-290)
Solid tumors - cancer
Phase 2 pivotial China trial initiation announced July 5, 2017.
BGB-A317
Urothelial cancer (UC) - bladder cancer
Phase 2 pivotal updated data presented at EHA June 2019 noted 87% ORR (63% CR).
Tislelizumab - BGB-A317
Relapsed or refractory classical Hodgkin lymphoma (cHL)
Phase 2 updated data at ICML June 19, 2019 - ORR was 83.7%; CR rate 77.9%.
Zanubrutinib (BGB-3111)
Relapsed or refractory mantle cell lymphoma (MCL)
Phase 3 data at EHA June 2019 noted 81% ORR. Further data due 2H 2019.
Zanubrutinib (BGB-3111)
Waldenström’s macroglobulinemia
Phase 3 commencement of enrolment announced December 17, 2018.
Tislelizumab - BGB-A317
Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2 data due 2019.
Tislelizumab
Hepatocellular carcinoma (HCC) - second-line
Phase 3 trial initiation announced July 24, 2018.
Pamiparib (BGB-290)
Gastric Cancer
Phase 3 trial commencement of enrollment announced May 17, 2018.
Pamiparib (BGB-290)
Maintenance Therapy Ovarian Cancer
Phase 3 trial initiation announced July 24, 2018.
Tislelizumab
Non-squamous non-small cell lung cancer (NSCLC)
Phase 3 trial initiation announced August 9, 2018.
Tislelizumab
Squamous non-small cell lung cancer (NSCLC)
Phase 1/2 data presented at SNO November 16, 2018 noted 2/15 partial responses.
Pamiparib (BGB-290)
Glioblastoma (GBM)
Phase 3 data due 2H 2019.
Zanubrutinib (BGB-3111) vs Ibrutinib
Refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Phase 1b initial data due 2H 2019.
Sitravatinib and tislelizumab
Solid tumors
Phase 3 commencement of enrolment announced December 17, 2018.
Tislelizumab
Gastric Cancer
Phase 1 updated data at EHA June 2019 noted 92% ORR.
Zanubrutinib (BGB-3111)
Waldenström’s macroglobulinemia
Phase 2 trial initiation announced February 19, 2019.
Zanubrutinib (BGB-3111) - MAGNOLIA
Marginal Zone Lymphoma
Phase 3 trial ongoing.
Tislelizumab
Nasopharyngeal cancer

Latest News

  1. Did You Miss BeiGene's (NASDAQ:BGNE) Whopping 327% Share Price Gain?
  2. Here's Why BeiGene Lost 11.6% in the First Half of 2019
  3. 3 Top Chinese Stocks to Watch in July
  4. Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
  5. BeiGene Granted Approval to Transition from the Biotech Chapter of the Hong Kong Stock Exchange to a General Listing
  6. The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)
  7. Here’s What Hedge Funds Think About BeiGene, Ltd. (BGNE)
  8. BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML)
  9. BeiGene Presents Pivotal Phase 2 Clinical Results of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML)
  10. BeiGene Announces Updated Results from Two Ongoing Clinical Trials of Zanubrutinib in Patients with Mantle Cell Lymphoma in Presentations at the 15th International Conference on Malignant Lymphoma (ICML)
  11. BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor
  12. BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab
  13. The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
  14. BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA)
  15. BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)
  16. BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)
  17. Is BeiGene, Ltd. (NASDAQ:BGNE) As Strong As Its Balance Sheet Indicates?
  18. BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
  19. BeiGene Chief Executive Officer John V. Oyler Elected to BIO Board of Directors
  20. BeiGene Announces Preliminary Phase 2 Results of Tislelizumab in Chinese Patients with Nasopharyngeal Cancer at the 2019 ASCO Annual Meeting